WO2005103702A3 - Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2) - Google Patents

Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2) Download PDF

Info

Publication number
WO2005103702A3
WO2005103702A3 PCT/EP2005/003631 EP2005003631W WO2005103702A3 WO 2005103702 A3 WO2005103702 A3 WO 2005103702A3 EP 2005003631 W EP2005003631 W EP 2005003631W WO 2005103702 A3 WO2005103702 A3 WO 2005103702A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
cxcr2
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2005/003631
Other languages
French (fr)
Other versions
WO2005103702A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2005103702A2 publication Critical patent/WO2005103702A2/en
Publication of WO2005103702A3 publication Critical patent/WO2005103702A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Abstract

The invention provides a human CXCR2 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders and cancer disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders and cancer disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of CXCR2 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/003631 2004-04-20 2005-04-07 Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2) WO2005103702A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04009254.6 2004-04-20
EP04009254 2004-04-20

Publications (2)

Publication Number Publication Date
WO2005103702A2 WO2005103702A2 (en) 2005-11-03
WO2005103702A3 true WO2005103702A3 (en) 2006-02-16

Family

ID=35058902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/003631 WO2005103702A2 (en) 2004-04-20 2005-04-07 Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2)

Country Status (1)

Country Link
WO (1) WO2005103702A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013276994C1 (en) * 2007-08-13 2016-08-11 Takeda Pharmaceutical Company Limited IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease
KR101247641B1 (en) 2010-10-22 2013-03-29 성균관대학교산학협력단 Composition of treatment for infectious and inflammatory diseases comprising peptide ligand binding to CXCR2
ES2723775T3 (en) 2010-11-08 2019-09-02 Ablynx Nv Polypeptides that bind to CXCR2
NZ589251A (en) 2010-11-12 2014-07-25 Pacific Edge Ltd Novel marker for detection of bladder cancer
WO2013148370A1 (en) 2012-03-30 2013-10-03 Sloan-Kettering Institute For Cancer Research S100a8/a9 as a diagnostic marker and a therapeutic target
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018641A1 (en) * 1991-04-10 1992-10-29 The Trustees Of Boston University Interleukin-8 receptors and related molecules and methods
US5374506A (en) * 1991-09-13 1994-12-20 The United States Of America As Represented By The Department Of Health And Human Services Amino acid sequence for a functional human interleukin-8 receptor
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US6548499B1 (en) * 1998-02-23 2003-04-15 Millennium Pharmaceuticals, Inc. Substituted quinoxaline derivatives as interleukin-8 receptor antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
WO1992018641A1 (en) * 1991-04-10 1992-10-29 The Trustees Of Boston University Interleukin-8 receptors and related molecules and methods
US5374506A (en) * 1991-09-13 1994-12-20 The United States Of America As Represented By The Department Of Health And Human Services Amino acid sequence for a functional human interleukin-8 receptor
US6548499B1 (en) * 1998-02-23 2003-04-15 Millennium Pharmaceuticals, Inc. Substituted quinoxaline derivatives as interleukin-8 receptor antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EDDLESTON JANE ET AL: "Bradykinin increases the in vivo expression of the CXC chemokine receptors CXCR1 and CXCR2 in patients with allergic rhinitis.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 111, no. 1, January 2003 (2003-01-01), pages 106 - 112, XP002349916, ISSN: 0091-6749 *
NOMURA ICHIRO ET AL: "Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: A gene microarray analysis.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 112, no. 6, December 2003 (2003-12-01), pages 1195 - 1202, XP002349917, ISSN: 0091-6749 *
OWEN CHARLES: "Chemokine receptors in airway disease: Which receptors to target?", PULMONARY PHARMACOLOGY AND THERAPEUTICS, vol. 14, no. 3, 2001, pages 193 - 202, XP002349915, ISSN: 1094-5539 *

Also Published As

Publication number Publication date
WO2005103702A2 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
WO2005106492A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
WO2005103702A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2)
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005106471A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2005106489A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 5 (ccr5)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2005103711A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005106488A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005108998A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2004104577A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
WO2005040824A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2005040822A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 25 (gpr25)
WO2004082572A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 87 (gpr87)
WO2005103690A3 (en) Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
WO2004106934A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase